Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease.

Hu CA, Klopfer EI, Ray PE.

FEBS Lett. 2012 Apr 5;586(7):947-55. doi: 10.1016/j.febslet.2012.03.002. Epub 2012 Mar 8. Review.

2.

The evolving science of apolipoprotein-L1 and kidney disease.

Chen TK, Estrella MM, Parekh RS.

Curr Opin Nephrol Hypertens. 2016 May;25(3):217-25. doi: 10.1097/MNH.0000000000000222. Review.

PMID:
27023839
3.

Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.

Chen TK, Choi MJ, Kao WH, Astor BC, Scialla JJ, Appel LJ, Li L, Lipkowitz MS, Wolf M, Parekh RS, Winkler CA, Estrella MM, Crews DC.

Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2128-35. doi: 10.2215/CJN.05220515. Epub 2015 Oct 1.

4.

Testing for High-Risk APOL1 Alleles in Potential Living Kidney Donors.

Riella LV, Sheridan AM.

Am J Kidney Dis. 2015 Sep;66(3):396-401. doi: 10.1053/j.ajkd.2015.04.046. Epub 2015 Jun 3.

PMID:
26049628
5.

Biogenesis and cytotoxicity of APOL1 renal risk variant proteins in hepatocytes and hepatoma cells.

Cheng D, Weckerle A, Yu Y, Ma L, Zhu X, Murea M, Freedman BI, Parks JS, Shelness GS.

J Lipid Res. 2015 Aug;56(8):1583-93. doi: 10.1194/jlr.M059733. Epub 2015 Jun 18.

6.

Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.

Khatua AK, Cheatham AM, Kruzel ED, Singhal PC, Skorecki K, Popik W.

Am J Physiol Cell Physiol. 2015 Jul 1;309(1):C22-37. doi: 10.1152/ajpcell.00384.2014. Epub 2015 Apr 29.

7.

APOL1 genetic variants, chronic kidney diseases and hypertension in mixed ancestry South Africans.

Matsha TE, Kengne AP, Masconi KL, Yako YY, Erasmus RT.

BMC Genet. 2015 Jun 26;16:69. doi: 10.1186/s12863-015-0228-6.

8.

APOL1 variants associate with increased risk of CKD among African Americans.

Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, Boerwinkle E, Parekh RS, Kao WH.

J Am Soc Nephrol. 2013 Sep;24(9):1484-91. doi: 10.1681/ASN.2013010113. Epub 2013 Jun 13.

9.

APOL1 Genotype and Glomerular and Tubular Kidney Injury in Women With HIV.

Jotwani V, Shlipak MG, Scherzer R, Parekh RS, Kao WH, Bennett M, Cohen MH, Nowicki M, Sharma A, Young M, Tien PC, Parikh CR, Estrella MM.

Am J Kidney Dis. 2015 Jun;65(6):889-98. doi: 10.1053/j.ajkd.2015.02.329. Epub 2015 Apr 24.

10.

Increased burden of cardiovascular disease in carriers of APOL1 genetic variants.

Ito K, Bick AG, Flannick J, Friedman DJ, Genovese G, Parfenov MG, Depalma SR, Gupta N, Gabriel SB, Taylor HA Jr, Fox ER, Newton-Cheh C, Kathiresan S, Hirschhorn JN, Altshuler DM, Pollak MR, Wilson JG, Seidman JG, Seidman C.

Circ Res. 2014 Feb 28;114(5):845-50. doi: 10.1161/CIRCRESAHA.114.302347. Epub 2013 Dec 30.

11.

APOL1 risk variants, race, and progression of chronic kidney disease.

Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ; AASK Study Investigators; CRIC Study Investigators.

N Engl J Med. 2013 Dec 5;369(23):2183-96. doi: 10.1056/NEJMoa1310345. Epub 2013 Nov 9.

12.

Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression.

Hawkins GA, Friedman DJ, Lu L, McWilliams DR, Chou JW, Sajuthi S, Divers J, Parekh RS, Li M, Genovese G, Pollack MR, Hicks PJ, Bowden DW, Ma L, Freedman BI, Langefeld CD.

Am J Nephrol. 2015;42(2):99-106. doi: 10.1159/000439448. Epub 2015 Sep 8.

13.

APOL1 toxin, innate immunity, and kidney injury.

Limou S, Dummer PD, Nelson GW, Kopp JB, Winkler CA.

Kidney Int. 2015 Jul;88(1):28-34. doi: 10.1038/ki.2015.109. Epub 2015 Apr 8. Review.

14.

APOL1 kidney risk alleles: population genetics and disease associations.

Limou S, Nelson GW, Kopp JB, Winkler CA.

Adv Chronic Kidney Dis. 2014 Sep;21(5):426-33. doi: 10.1053/j.ackd.2014.06.005. Review.

15.

Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease.

Freedman BI, Langefeld CD, Turner J, Núñez M, High KP, Spainhour M, Hicks PJ, Bowden DW, Reeves-Daniel AM, Murea M, Rocco MV, Divers J.

Kidney Int. 2012 Oct;82(7):805-11. doi: 10.1038/ki.2012.217. Epub 2012 Jun 13.

16.

Plasma apolipoprotein L1 levels do not correlate with CKD.

Bruggeman LA, O'Toole JF, Ross MD, Madhavan SM, Smurzynski M, Wu K, Bosch RJ, Gupta S, Pollak MR, Sedor JR, Kalayjian RC.

J Am Soc Nephrol. 2014 Mar;25(3):634-44. doi: 10.1681/ASN.2013070700. Epub 2013 Nov 14.

17.
18.

Apolipoprotein L1: from obscurity to consistency to controversy.

Lipkowitz MS.

Kidney Int. 2015 Jan;87(1):14-7. doi: 10.1038/ki.2014.319.

PMID:
25549121
19.

APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair.

Kofman T, Audard V, Narjoz C, Gribouval O, Matignon M, Leibler C, Desvaux D, Lang P, Grimbert P.

Am J Kidney Dis. 2014 May;63(5):816-9. doi: 10.1053/j.ajkd.2013.12.014. Epub 2014 Feb 8.

20.

High population frequencies of APOL1 risk variants are associated with increased prevalence of non-diabetic chronic kidney disease in the Igbo people from south-eastern Nigeria.

Ulasi II, Tzur S, Wasser WG, Shemer R, Kruzel E, Feigin E, Ijoma CK, Onodugo OD, Okoye JU, Arodiwe EB, Ifebunandu NA, Chukwuka CJ, Onyedum CC, Ijoma UN, Nna E, Onuigbo M, Rosset S, Skorecki K.

Nephron Clin Pract. 2013;123(1-2):123-8. doi: 10.1159/000353223. Epub 2013 Jul 13.

PMID:
23860441

Supplemental Content

Support Center